45 articles - From Friday Jul 29 2022 to Friday Aug 05 2022
Guidelines, position statements, white papers, technical reviews, consensus statements, etc…
meta-analyses and systematic reviews
RCT, clinical trials, retrospective studies, etc…
| Ann Rheum Dis |
Behçet's disease risk-variant HLA-B51/ERAP1-Hap10 alters human CD8 T cell immunity. Objectives The endoplasmic reticulum aminopeptidase ( at the cellular level and point to an HLA-B51-restricted process. Our findings suggest that variant ERAP1-Hap10 partakes in BD pathogenesis by generating HLA-B51-restricted peptides, causing a change in immunodominance of the ensuing CD8 T cell response. |
Cross-species transcriptome analysis for early detection and specific therapeutic targeting of human lupus nephritis. Machine-learning analysis of a large whole blood RNA-sequencing dataset of SLE patients using human orthologs of mouse kidney-specific genes can be used for early, non-invasive diagnosis and therapeutic targeting of LN. The kidney-specific gene predictors may facilitate prevention and early intervention trials. |
Distinct immune-effector and metabolic profile of CD8+ T cells in patients with autoimmune polyarthritis induced by therapy with immune checkpoint inhibitors. Our study shows that CD8 from ICI-treated patients who develop a musculoskeletal irAE has a distinct immune-effector and metabolic profile from those that remain irAE free. This specific irAE profile overlaps with the one observed in CD8 from AA patients and may prove useful for novel therapeutic strategies to manage ICI-induced irAEs. |
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial. Infections were higher with tofacitinib versus TNFi. Findings may inform future treatment decisions. |
Peroxisome proliferator activated receptor- PGZ was well tolerated and induced significant improvement in vascular stiffness and cardiometabolic parameters in SLE. The results suggest that PGZ should be further explored as a modulator of cardiovascular disease risk in SLE. |
| Arthritis Care Res (Hoboken) |
Cumulative Social Disadvantage is Associated with Childhood Arthritis: A Cross-Sectional Analysis of the National Survey of Children's Health. In this nationally representative sample, accumulated social disadvantage, measured via a cumulative social disadvantage score based on income level, guardian education, insurance status, and ACE exposure, was associated with an arthritis diagnosis and moderate-to-severe arthritis activity. |
Disease Recapture Rates After Medication Discontinuation and Flare in JIA: An Observational Study within the Childhood Arthritis and Rheumatology Research Alliance Registry. Approximately half of JIA flares post-discontinuation were recaptured within 6 months, but rates of recapture varied across JIA categories. These findings inform shared decision-making for patients, families, and clinicians regarding the risks and benefits of medication discontinuation. Better understanding of biologic predictors of successful recapture in JIA are needed. |
Do patients with intersectional disadvantage have poorer outcomes from osteoarthritis management programmes? A tapered-balancing study of patient outcomes from the Good Life with osteoArthritis in Denmark (GLA:D®) programme. Outcome inequalities widened following OAMP attendance, particularly at longer-term follow-up but the magnitude of differences was generally modest and inconsistent across outcome measures. Tailoring content to reduce outcome inequalities may be indicated but improving access appears the greater priority. |
Frequency and clinical utility of antibodies to extractable nuclear antigen in the setting of a negative antinuclear antibody test. A new AARD was diagnosed in 17/279 patients yielding a positive predictive value of 6.09% (95% CI 3.59-9.58) CONCLUSION: Despite the higher-than-expected incidence of positive ENA in the setting of a negative ANA, the yield of newly diagnosed rheumatic diseases was low. Our findings support the stepwise addition of ENA requests when an ANA is positive and clinical suspicion of an AARD is high. |
The long-term outcome and prognosis factor of patients with idiopathic inflammatory myopathies based on myositis-specific autoantibodies. Despite favorable overall survival in patients with IIM, the anti-MDA5-positive subgroup had the highest mortality among al the MSA subgroups, highlighting the distinctive prognosis of patients with different MSA. RP-ILD and malignancy are the most common causes of death of IIM patients. |
| Arthritis Res Ther |
Association of low-dose glucocorticoid use and infection occurrence in systemic lupus erythematosus patients: a prospective cohort study. Our results suggested that the use of 5.0-7.5 mg PSL or equivalent could pose an infection risk in SLE patients. This finding indicates that PSL dose should be reduced to as low as possible in SLE patients to avoid infection. |
Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study. HZ risk is significantly increased in RA patients with a history of HZ after the initiation of bDMARDs or tsDMARD. The risk of incident and recurrent HZ was higher after tofacitinib treatment in patients with RA than that after treatment with bDMARDs. Individualized characteristics and history of HZ should be considered when selecting bDMARDs or tsDMARD for RA patients considering HZ risks. |
Targeting clock-controlled gene Nrf2 ameliorates inflammation-induced intervertebral disc degeneration. Taken together, our study extends the relationship between peripheral clock and IVD homeostasis and provides a potential therapeutic method for the prevention and recovery of IDD by targeting the clock-controlled gene Nrf2. |
| Arthritis Rheumatol |
| Rheumatology (Oxford) |
Clinically suspect arthralgia patients with a low educational attainment have an increased risk to develop inflammatory arthritis. This is the first study providing evidence that lower educational attainment is associated with a higher risk of progressing from arthralgia to IA. This effect was partially mediated by subclinical joint inflammation. |
Coping strategies, emotional distress and perceived disease severity in a cohort of patients with rheumatoid arthritis: a mediation analysis. This study suggests that coping strategies could be an important factor in the perceived disease severity. Consequently, in order to reduce PGA in patients with RA, a useful tool could be represented by the implementation of psychological interventions aiming to modify the specific coping styles. Moreover, to prevent or treat emotional distress seems to further reduce PGA. |
Differences in symptom experience among patients with systemic sclerosis: A cluster analytic approach to identifying subgroups. Identification of distinct symptom clusters, particularly among SSc patients who experience mild and moderate symptoms, suggest potential differences in treatment approach and in mechanisms underlying symptom experience that require further study. |
Different Covid-19 Outcomes Among Systemic Rheumatic Diseases: A Nation-wide Cohort Study. Covid-19 may have more severe impact in patients with systemic rheumatic disease than the general population. Covid-19-related mortality is increased in subgroups of patients with specific rheumatic diseases, underscoring the need for priority vaccination and access to targeted treatments. |
Effectiveness of the BNT162b2 mRNA COVID-19 Vaccine among Adolescents with Juvenile-onset Inflammatory Rheumatic Diseases. We found that the BNT162b2 mRNA vaccine is effective against COVID-19 infection in adolescents with IRD, similar to controls without immune rheumatic disease. Immunomodulatory therapy did not affect its effectiveness. These results can encourage adolescents with IRD to get vaccinated against COVID-19. |
Fibroblast expression of CD248 may contribute to exacerbate microvascular damage during systemic sclerosis. CD248 was anti-angiogenic in vitro due to reduction the tube formation and to induction of ECs apoptosis. Increased expression of CD248 in SSc could contribute to the microvascular rarefaction observed at tissue level during SSc. Our results suggest the pathogenic role of CD248-MMRN-2 in SSc. |
Impaired physical function in patients with idiopathic inflammatory myopathies: results from the multicentre COVAD patient-reported e-survey. Physical function is significantly impaired in IIMs compared with non-IIM AIRDs or HCs, even in patients with inactive disease. Our study highlights a critical need for better strategies to minimize functional disability in patients with IIMs. |
JAK inhibitors in difficult-to-treat adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. JAKi agents may be a therapeutic option for some patients with difficult-to-treat Still's disease, especially those with partial response to medium- or high-dose corticosteroids or biologics. |
Long-term follow-up of Janus-kinase inhibitor and novel active disease biomarker in juvenile dermatomyositis. The preliminary evidence suggested that JAKi is a relatively safe and effective alternative for JDM patients. Cytokine profiles could well reflect the inflammatory status of JDM patients. |
Plasma proteomics identifies CRTAC1 as a biomarker for osteoarthritis severity and progression. We identified several compelling biomarkers reflecting overall osteoarthritis burden and increased risk for osteoarthritis progression. CRTAC1 was the most compelling and robust biomarker for osteoarthritis severity and progression. Such a biomarker may be used for disease monitoring. |
Prevalence of non-celiac gluten sensitivity and assessment of the response to gluten-free diet in a cohort of patients with fibromyalgia. A NCGS prevalence similar to that estimated in the general population was found. A GFD cannot be systematically recommended to al patients with Fibromyalgia, although it could be evaluated in those with diarrhea or intraepithelial lymphocytosis to evaluate if there are improvements in their intestinal symptoms. |
Reduced Cathepsin L Expression and Secretion into the Extracellular Milieu Contribute to Lung Fibrosis in Systemic Sclerosis. Our findings identify CTSL as a protein protective against lung fibrosis via its activation of antifibrotic ES, and whose expression in SSc pLFs and lung tissues is suppressed. Identifying strategies to boost CTSL endogenous levels in SSc patients could serve as a viable therapeutic strategy. |
Soluble guanylate cyclase stimulation fosters angiogenesis and blunts myofibroblast-like features of systemic sclerosis endothelial cells. These findings demonstrate for the first time that pharmacological sGC stimulation effectively ameliorates the angiogenic performance and blunts the myofibroblast-like profibrotic phenotype of SSc-MVECs, thus providing new evidence for repurposing sGCSs for SSc. |
Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model. The DU-VASC model, with good calibration and discrimination ability, revealed that PIs treatment was the most important therapy-related predictor associated with reduced DUs occurrence. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Arthritis Rheumatol |
Letters to the editors and authors’ replies
all remaining publications eg case reports, images of the month, etc…
| Ann Rheum Dis |
| Arthritis Care Res (Hoboken) |
| Arthritis Rheumatol |
| Rheumatology (Oxford) |